Blood test could predict best liver cancer therapy
NCT ID NCT04459468
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked for proteins in the blood that might predict how well liver cancer treatments work. Researchers took blood samples from 17 patients before and after standard treatments like TACE or ablation. The goal was to find biomarkers that could help doctors choose the best treatment for each patient. No new treatment was tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that helps doctors choose the best treatment for liver cancer patients.
- What could go wrong
- This was a very small study (17 people) that only looked for markers, not a treatment. The findings may not apply to all patients or lead to a usable test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?